List of Excipients in Branded Drug DEXCHLORPHENIRAMINE MALEATE

« Back to Dashboard

Generic Drugs Containing DEXCHLORPHENIRAMINE MALEATE

Company	Ingredient	NDC	Excipient
Foxland Pharmaceuticals Inc	dexchlorpheniramine maleate	69067-102	CITRIC ACID MONOHYDRATE
Foxland Pharmaceuticals Inc	dexchlorpheniramine maleate	69067-102	FD&C RED NO. 40
Foxland Pharmaceuticals Inc	dexchlorpheniramine maleate	69067-102	GLYCERIN
Foxland Pharmaceuticals Inc	dexchlorpheniramine maleate	69067-102	MENTHOL

What are the Most Frequently-Used Excipients in DEXCHLORPHENIRAMINE MALEATE?

# Of NDCs	Excipient
1	CITRIC ACID MONOHYDRATE
1	FD&C RED NO. 40
1	GLYCERIN
1	MENTHOL

Dexchlorpheniramine Maleate Excipient Strategy and Commercial Opportunities

Last updated: September 29, 2026

Dexchlorpheniramine maleate is a mature, first-generation H1 antihistamine with low API cost, established pharmacology, and limited standalone patent differentiation. Commercial opportunities are concentrated in formulation execution: palatable oral liquids, low-sugar or sugar-free products, orally disintegrating tablets, combination products, pediatric presentations, and region-specific OTC or prescription strategies. The strongest value proposition is usually improved usability rather than new clinical efficacy.

What is dexchlorpheniramine maleate and how is it commercialized?

Dexchlorpheniramine maleate is the maleate salt of dexchlorpheniramine, the d-isomer of chlorpheniramine. It is used for allergic rhinitis, urticaria, and other histamine-mediated conditions. The compound is a sedating first-generation antihistamine with anticholinergic effects.

Attribute	Commercial relevance
Active ingredient	Dexchlorpheniramine maleate
Pharmacologic class	First-generation H1 antihistamine
Common dosage forms	Tablets, extended-release tablets, oral solutions, syrups, combination products
Typical immediate-release strengths	2 mg tablets; liquid products commonly expressed as 0.4 mg/mL, subject to market
Extended-release strength	Commonly 6 mg products in markets where available
Administration	Oral
Primary use	Allergy and urticaria symptom relief
Key tolerability issue	Drowsiness, dry mouth, blurred vision, urinary retention
Main formulation risks	Bitter taste, dose uniformity at low strength, preservative stability, sugar content
Patent profile	Mature active ingredient with limited standalone composition-of-matter value
Main commercial advantage	Low-cost, familiar antihistamine platform

Historical products have included Polaramine and Polaramine Repetabs, although product availability and regulatory status vary by jurisdiction. Dexchlorpheniramine may be marketed as a standalone product or combined with decongestants, antitussives, analgesics, or other cold and allergy ingredients.

The US commercial environment is fragmented. Older prescription products have been discontinued or have had limited availability, while products in other countries may remain marketed under prescription or nonprescription pathways. FDA approval and marketing status must be assessed product by product through Drugs@FDA, the Orange Book, and current labeling databases. [1-3]

What excipients are most suitable for dexchlorpheniramine maleate tablets?

The preferred tablet excipient system depends on dose, target market, release profile, and whether the product is conventional, chewable, or orally disintegrating.

Immediate-release tablets

A conventional immediate-release tablet can use a direct-compression or wet-granulation platform. Dexchlorpheniramine maleate is administered at a low dose, so content uniformity is a central development issue.

Formulation function	Candidate excipients	Strategic purpose
Diluent	Microcrystalline cellulose, lactose monohydrate, mannitol, dibasic calcium phosphate	Builds tablet mass and supports uniform API distribution
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Promotes rapid tablet breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate	Supports manufacturing ejection
Glidant	Colloidal silicon dioxide	Improves powder flow
Sweetener	Sucralose, aspartame, acesulfame potassium, mannitol	Relevant for chewable or orally disintegrating forms
Flavor	Mint, berry, citrus, vanilla	Masks bitterness and improves adherence
Film coat	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide or approved colorants	Improves swallowability, appearance, and light protection

For low-dose tablets, geometric dilution or ordered blending is more important than simply increasing excipient concentration. Segregation can occur when the API and filler have materially different particle sizes, densities, or electrostatic behavior. Co-processed excipients can reduce process variability, but they may increase cost and complicate global sourcing.

Lactose is commercially efficient but may be unsuitable for products targeting lactose-intolerant consumers or markets that prefer lactose-free formulations. Mannitol provides a cooling mouthfeel and is useful in chewable and orally disintegrating products. Microcrystalline cellulose supports robust compaction but can produce a less pleasant mouthfeel in chewable tablets.

Extended-release tablets

Extended-release dexchlorpheniramine products have historically used matrix or coated-system approaches. The commercial objective is to reduce dosing frequency while avoiding dose dumping and excessive sedation.

Potential release-controlling materials include:

• Hypromellose of selected viscosity grades
• Ethylcellulose
• Ammonio methacrylate copolymers
• Polyvinyl acetate-based matrix systems
• Lipophilic waxes or fatty excipients

A matrix tablet is usually simpler and cheaper than a multiparticulate system. Coated pellets or granules provide greater control over release but create additional manufacturing and scale-up requirements. The formulation must demonstrate comparable dissolution across pH conditions and adequate robustness against alcohol exposure where required by the applicable regulatory authority.

Extended-release products have greater differentiation potential than immediate-release tablets, but they also carry higher regulatory and development risk. A new extended-release version would generally require pharmacokinetic and comparative dissolution evidence rather than relying only on historical product data.

What excipients are appropriate for dexchlorpheniramine maleate oral liquids?

Oral liquid products offer the clearest formulation opportunity because the API dose is low, the target population includes children and older adults, and taste can determine repeat use.

Typical oral-liquid platform

A dexchlorpheniramine oral solution may contain the following functional groups:

Function	Candidate excipients
Vehicle	Purified water
Sweetener	Sucrose, sorbitol, glycerol, xylitol, sucralose
Viscosity modifier	Hydroxyethylcellulose, xanthan gum, sodium carboxymethylcellulose
Buffer	Citrate, phosphate, acetate systems
Preservative	Sodium benzoate, benzoic acid, potassium sorbate
Chelator	Disodium EDTA
Flavor	Cherry, grape, orange, raspberry, mint
Solubilization aid	Propylene glycol, glycerol, polysorbate 80 where justified
Color	Market-permitted water-soluble colorants

The most commercially practical formulation is often a clear, ready-to-use, sugar-free solution with a calibrated dosing device. Sugar-free products can use sorbitol, glycerol, xylitol, or a high-intensity sweetener system. Polyols can cause gastrointestinal discomfort at higher exposures, and xylitol creates toxicologic concerns for household pets. Product labeling and packaging should account for these issues.

Preservative selection requires compatibility testing against pH, container closure, flavor, and surfactant components. Benzoate systems are widely used in acidic liquids, while sorbate systems can provide an alternative depending on pH and microbial challenge-test results. EDTA may improve preservative performance by reducing metal-catalyzed degradation and weakening microbial cell-envelope defenses, but it should be justified rather than added by default.

The API's salt form, pH-solubility behavior, and taste profile should be established before selecting the vehicle. A formulation that increases apparent solubility but produces intense bitterness may have poorer commercial performance than a suspension or taste-masked system.

Pediatric formulation opportunity

Pediatric products should prioritize:

1. A low-volume dose.
2. A measuring syringe rather than a household teaspoon.
3. Sugar-free and alcohol-free positioning.
4. Strong bitterness suppression.
5. Clear concentration labeling.
6. Child-resistant packaging where required.
7. Minimal excipient burden.

A 0.4 mg/mL concentration allows a 2 mg dose to be delivered in 5 mL, but higher concentrations can reduce dosing volume. Concentration selection must balance administration burden against dosing-error risk. FDA guidance emphasizes age-appropriate dosing devices and clear labeling for liquid medicines. [4]

How can dexchlorpheniramine maleate taste be masked?

Taste masking is likely to determine the success of a chewable, orally disintegrating, or pediatric product. Dexchlorpheniramine maleate is expected to present a bitter pharmaceutical taste typical of many antihistamines.

Taste-masking approaches

Approach	Advantages	Limitations
High-intensity sweetener and flavor system	Low cost, simple manufacturing	Often insufficient for persistent bitterness
Polymer coating	Stronger barrier and longer taste protection	Adds process complexity
Ion-exchange resin complex	Useful for liquid and chewable formats	Requires resin screening and release validation
Cyclodextrin complexation	May improve taste and apparent solubility	Can increase excipient load and cost
Lipid or wax coating	Effective barrier in solid products	May delay dissolution
Microencapsulation	Supports liquid suspension and chewables	Requires particle-size and release control
Effervescent system	Rapid dispersion and sensory masking	Moisture sensitivity and packaging burden

Ion-exchange resins are attractive when the API is sufficiently ionizable and the complex remains stable during storage but releases rapidly under gastrointestinal conditions. Polymer-coated microparticles can support a ready-to-use suspension, but sedimentation, redispersibility, and dose uniformity become critical.

A layered strategy often works best: reduce free API in the mouth through coating or complexation, then use a sweetener-flavor system to manage residual bitterness. Excessive flavor can create its own acceptability problems and may increase regulatory review complexity.

What formulation patents could protect dexchlorpheniramine products?

The mature API is unlikely to support broad new composition-of-matter protection. Commercial protection is more likely to arise from narrow formulation, delivery, or combination claims.

Potentially protectable areas include:

• Extended-release matrices with defined dissolution profiles.
• Taste-masked dexchlorpheniramine particles.
• Stable preservative-free oral solutions.
• Low-sugar or sugar-free liquid systems.
• Orally disintegrating tablets with defined disintegration and dissolution characteristics.
• Combination products with a specified weight ratio of active ingredients.
• Unit-dose sachets or stick packs.
• Manufacturing processes that improve content uniformity.
• Specific particle-size distributions or coating thicknesses.
• Packaging systems that improve moisture or light stability.

Patent strength depends on claim breadth, demonstrated technical effect, and the availability of design-around routes. A claim directed only to a conventional combination of dexchlorpheniramine, mannitol, crospovidone, and magnesium stearate would face substantial obviousness risk. A stronger position would require an unexpected stability, taste, release, or manufacturability result supported by comparative data.

Orange Book and method-of-use status

The Orange Book lists FDA-approved drug products and associated patent and exclusivity information for eligible products. [2] For a mature dexchlorpheniramine product, the key questions are whether an active NDA remains marketed, whether patents are listed against that NDA, and whether any listed method-of-use or formulation claims remain unexpired.

A standalone product with no active listed patents would generally present a lower US entry barrier, subject to the applicable abbreviated new drug application pathway and reference-product availability. Method-of-use patents may have limited practical value where the labeled indication is broad and the product's therapeutic use is longstanding.

Paragraph IV challenges would matter only if an ANDA applicant were addressing an unexpired Orange Book-listed patent. In the absence of a current listed patent, the filing strategy would not depend on a Paragraph IV certification. FDA's Approved Drug Products with Therapeutic Equivalence Evaluations and Drugs@FDA remain the relevant public sources. [1,2]

When does dexchlorpheniramine lose exclusivity?

Dexchlorpheniramine's original composition-of-matter and basic product exclusivity periods expired decades ago. The current commercial question is not loss of original exclusivity but whether any particular product has residual protection from formulation patents, regulatory exclusivity, trademarks, or market-specific requirements.

Protection category	Likely status for mature dexchlorpheniramine products
Original compound patent	Expired
Original basic formulation protection	Expired or commercially immaterial
Current formulation patents	Product- and jurisdiction-specific
US New Chemical Entity exclusivity	Expired
US pediatric exclusivity	Not expected to create a current barrier absent a qualifying recent product
Orphan exclusivity	Not generally associated with the core antihistamine use
Trademark protection	May remain active for specific brand names
Regulatory exclusivity outside the US	Varies by jurisdiction and product history

The principal barriers are therefore regulatory execution, manufacturing economics, distribution, and brand recognition rather than foundational patent rights.

What generic entry risks exist for dexchlorpheniramine?

Generic entry risk is high for conventional immediate-release tablets and standard oral solutions. The API is established, the dosage forms are technically familiar, and multiple excipient platforms can likely achieve equivalent performance.

Risk is lower, or at least more complex, for:

• Extended-release products.
• Taste-masked pediatric liquids.
• Orally disintegrating products.
• Complex combinations.
• Preservative-free multi-dose liquids.
• Products requiring a proprietary delivery device.
• Markets with limited API suppliers or stringent local manufacturing rules.

For an immediate-release tablet, bioequivalence may be straightforward if the product meets applicable waiver criteria and the strength and dissolution profile are suitable. Modified-release products generally require more extensive evidence. Liquid products may require comparative pharmacokinetic studies unless the jurisdiction permits a biowaiver based on formulation and physicochemical equivalence.

Which companies are competing in dexchlorpheniramine?

Competition is fragmented across regional manufacturers, generic companies, branded-generic suppliers, and combination-product marketers. Relevant competitors may include manufacturers of:

• Dexchlorpheniramine tablets.
• Dexchlorpheniramine oral solutions.
• Chlorpheniramine products.
• Loratadine, cetirizine, levocetirizine, and fexofenadine.
• Combination cold and allergy products.

The most important commercial comparison is not necessarily another dexchlorpheniramine product. Second-generation antihistamines compete on reduced sedation and once-daily dosing. Dexchlorpheniramine competes where low price, established physician familiarity, rapid access, or regional prescribing habits outweigh the disadvantages of sedation.

Dexchlorpheniramine versus competing antihistamines

Product class	Main advantage	Main disadvantage	Commercial implication
Dexchlorpheniramine	Low-cost, established, effective H1 blockade	Sedation and anticholinergic effects	Value and regional generic opportunity
Chlorpheniramine	Broad historical use and low cost	Sedation; racemic mixture	Competes on price and availability
Cetirizine/levocetirizine	Strong allergy positioning, usually less sedating	Some patients still experience drowsiness	Stronger modern allergy positioning
Loratadine	Once-daily, low-sedation profile	Less suitable where rapid sedating effect is desired	OTC brand and generic competition
Fexofenadine	Minimal central sedation	Higher cost in some markets	Premium non-sedating positioning

What manufacturing and supply-chain barriers affect commercial launch?

The API itself is not likely to be the main barrier. The more important risks are low-dose uniformity, impurity control, salt-form consistency, and dependable supply of formulation excipients.

Manufacturing priorities

• Establish API particle-size and bulk-density specifications.
• Control blend uniformity at the low-dose level.
• Validate sampling plans for content uniformity.
• Use low-shear blending where segregation is a concern.
• Confirm lubricant sensitivity and dissolution impact.
• Validate preservative efficacy for liquids.
• Test container-closure compatibility.
• Assess photostability and thermal stability.
• Qualify multiple API and critical-excipient suppliers.
• Use calibrated oral syringes for liquid products.
• Control residual solvents and elemental impurities according to applicable ICH requirements.

For liquids, packaging can create a larger risk than the formulation. Sorption into plastic, leachables, cap liner interaction, and evaporation through the closure can alter potency or preservative concentration. Amber PET, HDPE, or glass may be appropriate depending on stability data, but packaging selection should be based on real-time and accelerated studies rather than standard practice alone.

What licensing and partnership opportunities exist?

Licensing opportunities are more likely to involve products than the API. Potential transactions include:

1. Regional rights for a branded-generic oral solution.
2. Contract development of a pediatric sugar-free formulation.
3. Licensing of a taste-masking platform.
4. Private-label supply for pharmacy and retail chains.
5. Combination-product partnerships with decongestant or analgesic manufacturers.
6. Transfer of an extended-release formulation and regulatory dossier.
7. Local manufacturing partnerships in countries with domestic production incentives.

A conventional tablet has limited licensing value unless the partner brings distribution, tender access, or a protected brand. A stable, palatable pediatric liquid or differentiated extended-release product can command stronger commercial interest because the formulation and regulatory dossier reduce development time.

What is the revenue opportunity for dexchlorpheniramine products?

Revenue potential is usually modest on a global basis but can be attractive in focused markets. The category is price-sensitive, and generic competition limits gross margins for undifferentiated tablets.

Product concept	Revenue potential	Margin potential	Development risk
Standard 2 mg tablet	Low to moderate	Low	Low
Sugar-free oral solution	Moderate	Moderate	Moderate
Pediatric taste-masked liquid	Moderate to high in selected markets	Moderate to high	Moderate
Orally disintegrating tablet	Moderate	Moderate	Moderate
Extended-release tablet	Moderate	Higher if differentiated	High
Combination cold/allergy product	Moderate	Variable	Moderate
Proprietary delivery system	High if accepted	Potentially high	High

The strongest opportunity is a differentiated product that addresses an identifiable problem: unpleasant taste, dosing inconvenience, sugar content, swallowing difficulty, or dosing frequency. A new tablet with no patient-use advantage is unlikely to support premium pricing.

How should a commercial development program be prioritized?

A practical development sequence is:

Phase 1: Select the market and dosage form

Choose the target jurisdiction, prescription or OTC pathway, reference product, and intended patient segment. Regulatory classification changes the evidence package and labeling requirements.

Phase 2: Screen excipient systems

For tablets, compare direct compression with granulation and assess content uniformity. For liquids, screen vehicle, sweetener, preservative, buffer, flavor, and container closure together.

Phase 3: Quantify differentiation

Measure taste, dosing accuracy, disintegration, dissolution, stability, and patient usability. A product should have a measurable advantage before additional patent or licensing investment.

Phase 4: Build the protection strategy

File formulation or process applications only after identifying a defensible technical effect. Protect the brand, device, packaging, and manufacturing know-how in parallel.

Phase 5: Confirm regulatory and supply economics

Review reference-product status, bioequivalence requirements, excipient acceptability, API sourcing, minimum order quantities, and expected price erosion.

Key Takeaways

• Dexchlorpheniramine maleate is a mature antihistamine with limited standalone patent value.
• Immediate-release tablets and standard oral solutions face high generic-entry risk.
• The strongest formulation opportunities are pediatric liquids, taste-masked products, orally disintegrating tablets, and extended-release systems.
• Excipients should be selected around content uniformity, taste, preservative performance, dissolution, and packaging compatibility.
• Sugar-free, alcohol-free, low-volume oral solutions offer a practical commercial niche.
• Formulation patents need a demonstrated technical effect to withstand obviousness challenges.
• Original compound exclusivity has expired; current barriers are product-specific patents, regulatory requirements, manufacturing quality, and distribution.
• Licensing value is concentrated in differentiated formulations, regulatory dossiers, regional rights, and retail or tender access.
• Second-generation antihistamines remain the principal commercial competitors because of lower sedation and convenient dosing.
• A differentiated product with patient-use benefits has better revenue potential than an undifferentiated low-cost tablet.

Frequently Asked Questions

Is dexchlorpheniramine maleate still commercially viable?

Yes, but mainly in targeted markets and differentiated dosage forms. Conventional tablets are likely to be highly price-competitive, while pediatric liquids, sugar-free products, and taste-masked formulations can support better margins.

Which excipient is best for masking dexchlorpheniramine bitterness?

No single excipient is universally optimal. Ion-exchange resins, polymer coatings, microencapsulation, cyclodextrins, and layered sweetener-flavor systems are the main platforms requiring comparative screening.

Can dexchlorpheniramine maleate be formulated as a preservative-free oral solution?

Potentially, but the product would need a validated microbial-control strategy. Unit-dose packaging, aseptic manufacture, low-water-activity systems, or other validated approaches may be required depending on the formulation and regulatory pathway.

Does dexchlorpheniramine maleate have biosimilar risk?

No. Dexchlorpheniramine maleate is a small-molecule drug, so the relevant competition is generic or hybrid-drug competition, not biosimilar competition.

Are dexchlorpheniramine combination products patentable?

They can be, but patent strength depends on the specific combination, dosage ratio, release profile, clinical use, or technical effect. Conventional combinations with predictable antihistamine and decongestant components face higher validity risk.

References

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
3. DailyMed. (n.d.). Drug labeling database. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/
4. U.S. Food and Drug Administration. (2015). Use of liquid dosage forms by children. In Guidance for industry: Safety considerations for container labels and carton labeling design to minimize medication errors. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-considerations-container-labels-and-carton-labeling-design-minimize-medication-errors